TABLE 3.

Effects of the ABCB1 Genotypes on Adjusted Levetiracetam Serum Concentrations

SNPs	Genotype	Number (%)	Serum Concentration, µg·mL−1	F/Z	P	CDR, µg·mL−1·kg·mg−1	F/t	P
C1236T	CC	37 (15)	13.04 ± 4.24	F = 0.205	0.814	0.37 ± 0.14	F = 0.302	0.740
	CT	111 (45)	13.56 ± 4.69			0.38 ± 0.14
	TT	97 (40)	13.29 ± 4.60			0.39 ± 0.12
	CT + TT versus CC	208 (85)	13.44 ± 4.64	Z = −0.306	0.760	0.39 ± 0.13	Z = −0.875	0.381
G2677T/A	GG	44 (18)	11.76 ± 3.27	F = 2.211	0.068	0.32 ± 0.11	F = 4.906	0.001*
	GT	120 (49)	13.57 ± 4.40			0.38 ± 0.14
	TT	46 (19)	14.28 ± 5.03			0.43 ± 0.10
	GA	25 (10)	13.06 ± 4.66			0.38 ± 0.13
	AT	10 (4)	14.84 ± 7.11			0.45 ± 0.13
	GT + TT + GA + AT versus GG	201 (82)	13.76 ± 4.73	Z = −2.310	0.021*	0.40 ± 0.13	Z = −3.325	0.001*
C3435T	CC	78 (32)	12.63 ± 3.84	F = 6.392	0.002*	0.34 ± 0.12	F = 17.800	<0.001*
	CT	111 (45)	12.96 ± 4.70			0.38 ± 0.14
	TT	56 (23)	15.24 ± 4.72			0.47 ± 0.09
	CT + TT versus CC	167 (68)	13.72 ± 4.81	Z = −1.564	0.118	0.41 ± 0.14	Z = −3.752	<0.001*

^*P-value < 0.05 (2-sided) was considered statistically significant.